London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
You can write that again.
At Recordati's current launch rates, it's going to take them 20 years to launch in all their agreed territories and JG will still be getting his 1.5 mill plus inflationary increases. Wow.....just think how much he will have pocketed by then...lol
Hoping JG's well overdue 'comprehensive update' is soon and more positive as its been a dismal 2019.
good of you to take the initiative bunion.lets see what is said.
I wonder why he didn't write "something more concrete"..... Lol
I have emailed JG suggesting that an update is urgently needed regarding the UK and European Fortacin relaunches, plus the Hong Kong and Macau launches, progress with China plus US approvals progress........he has promised a comprehensive update ............
If they are waiting, there is no reason to pay JG his salary since he cannot be doing anything n est pa ?
I believe they are waiting on the China and USA approval. Demonstrations in Hong Kong not helping the SP.
Bothwell,
I'm sure we will see the fruits of our patience. We just need to cross the last couple of hurdles. Mainly the FDA. This in my opinion will, with the allowed advertising, bare fruit not just in the US, but ultimately the ROW.
The A team will not respond due to them realising it would indeed be admitting to incompetence. A CEO getting paid 1.5mill USD for decimating a companies SP through lack of foresight, professionalism and experience in an unrelated field whilst being supported by a BOD who all suffer from the same traits is incredible.
I personally stay, like others who have posted the same, because I have faith in the product which will eventually come good even at the hands of incompetence. It just takes a little longer... ;-)
As I've stated before, its like treating children. Ignore and they will eventually give up and go away. Unfortunately there are always one or two who just cannot help themselves and feed a narcists hunger for an audience....Oh and there's another one, ce la vie.......
Well Bignose I shouldn’t have asked. Pension down the tubes now. Hope someone can give some answers to the contrary..... Been here so long. Haven’t had any response from JM or JG.
Bothwell, as far as dependence on future return from Fortacin goes, the answer is "yes and "yes".
Sales simply reflect a reality that RP has chosen to ignore: that, while no worse than other PE treatments, Fortacin lacks the attributes required to attract and retain presribers and punters and meaningfully expand a very small market.
These flaws are inherent in Fortacin's make up and will continue to constrain uptake in Europe and in any future sales territories. If that were not enough, add in the impact of limited clinical and safety data, no patent protection and residual/minimal market exclusivity, no reimbursement under public or private healthcare plans and significant pricing pressure and competition from products already ensconced in the prescriber/distance prescribing channels.
Not only is the Fortacin pie always going to be on the teenie weenie side, but if you understand how deal terms relate to value split, RP will only ever see the crumbs.
A bit neg?, Well, yes, but I defy anyone to come up with a credible scenario where Fortacin rocks on as top dog, rather than being the runt of the litter, feebly scratching at the sack en route to the local duckpond.
SOTRR belated thank you for the information yesterday.
Bothwell,
There you go letting the side down. Why do you think it postes here ? Because it knows someone will respond. It has been posting its narcistic views for the last 5 years. It has a serious problem and you have just provided it with further encouragement.
So Alquemie are we wasting our time and have lost our money?
I'm thinking of taking up meditation as I'm fed up sitting around doing nothing.
Anyone?
I'm here all weekend.
Not singling you out, but like the other broken pencils, you are missing the point.
Recordati sees so much potential for UK sales that it's gone for an exclusive arrangement with a single online pharmacy. There is nothing underway in the form of targeted or shotgun promotion to prescribers on the understandable basis that no independent advisory (DTAB, the updated RTDC opinion) or CCG has ever expressed a positive opinion regarding Fortacin, and that it remains uniformly black or grey-listed.
Fortacin's problem is, uh, Fortacin- same mediocre performance as other PE treatments and no post-approval data to show that it's any different to yer common or garden, six-fold cheaper, knob spray containing the same pharmaceutical active but with a more benign safety profile. Hardly a platform for prescriber engagement.
And according to Recordati's own little SurveyMonkey efforts, only 4 out of 10 blokes are wiling to pony up again for a treatment which is claimed to be the answer to their prayers.
After over a full year in the market, net sales at the half year amounted to less than 0.08% of Recordati's pharma only revenue and generic silodosin introduction means the whole urology franchise is being wound down in once key territories.
Seriously, is there anyone who still believes that this is ever going to return more than Friday noodles and ice cream money?
Thanks SOTRR for the info.
So at ÂŁ39.99 for 12 doses you're looking at just over ÂŁ3 per go. For those with the condition I'd say that should encourage them to try it and hopefully with enough help from the those promoting it to the health professionals it should (in theory) sell better this time around. And although it will take longer for royals to come in and cover the costs of the CEO it is vital now that volumes pick up and word gets out there more rapidly. Its then a numbers game with in theory more awareness, more sales. Fingers crossed on this development.
https://www.medicines.org.uk/emc/files/pil.9620.pdf
Does this mean that new batches have now been produced and we may finally get HK and Macau launched..Thats once Orient receive the part batch from Recordati and someone with a big black marker puts a line through Recordati and writes above "Orient" and on the bottom "Made in Hong Kong"....LOL
Good spot. Looks promising.
Email from Doctor-4-U, now offering Fortacin 5ml for ÂŁ39.99 in Recordati branded packaging.